Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Mexican Registry of Neurologic Manifestations in Patients with Confirmed COVID-19: Preliminary Results
Infectious Disease
Infectious Disease Posters (7:00 AM-5:00 PM)
003
To describe the neurologic manifestations and complications of Mexican patients with confirmed coronavirus disease 2019 (COVID-19).
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was confirmed to have reached Mexico in February 2020. At present, Mexico is one of the most affected countries by the pandemic of COVID-19 worldwide. In the first months of the pandemic, only a few Mexican studies on COVID-19 had been reported. Scarce national data limited our understanding of the unique nuances that may occur in our setting and hindered the interpretation of evidence from other countries in the local context.

In March 2020, the Mexican Academy of Neurology (MAN) launched a national registry to have a clearer picture of the full spectrum of neurologic manifestations and complications of COVID-19 in Mexican patients. This online registry was available to all MAN members. Only patients with SARS-CoV-2 detected by real-time RT-PCR were included in this analysis.
At the end of August 2020, 89 patients (31 women, 34.8%) have been included. Their mean age was 50.5±18.8 years. Most cases were reported in central and southern regions (96%). Most patients showed respiratory symptoms (87%) and were admitted to hospital (88%). Among severe neurologic manifestations, vascular etiologies were the most commonly reported: ischemic stroke (n=17), intraparenchymal hemorrhage (n=6), and subarachnoid hemorrhage (n=4). Olfactory and gustatory dysfunctions were reported in 34 and 26 patients. Headache and delirium were reported in 54 and 18 patients. 7 patients had seizures. Meningitis and encephalitis were reported in 2 and 5 patients. 5 cases of Guillain-Barré syndrome were reported; three of them were classified as axonal variants. Neurologic sequelae were reported in 30 patients (33%). 19 (21%) patients died.
In this nationwide registry, one in five patients with COVID-19 and neurologic manifestations died. Cerebrovascular insults were the most common severe neurologic manifestations.
Authors/Disclosures
Guillermo R. Delgado-Garcia, MD, MSc (University of Calgary - Alberta Health Services)
PRESENTER 		Dr. Delgado-Garcia has received research support from Consejo Nacional de Ciencia y Tecnologia (Mexico). Dr. Delgado-Garcia has received research support from Consejo Nacional de Ciencia y Tecnologia (Mexico). Dr. Delgado-Garcia has a non-compensated relationship as a Editorial Team Member with Neurology Resident & Fellow Section that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Delgado-Garcia has a non-compensated relationship as a Editorial Board Member with Brain and Life en Espanol that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Delgado-Garcia has a non-compensated relationship as a Editorial Board Member with Neurology Clinical Practice that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Luis Davila Maldonado, MD (INCMNSZ) Dr. Davila Maldonado has nothing to disclose.
No disclosure on file
No disclosure on file